Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients

AIMS: Renin–angiotensin–aldosterone system (RAAS) inhibitors are well established for the reduction in cardiovascular morbidity, but their impact on all-cause mortality in hypertensive patients is uncertain. Our objective was to analyse the effects of RAAS inhibitors as a class of drugs, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vark, Laura C., Bertrand, Michel, Akkerhuis, K. Martijn, Brugts, Jasper J., Fox, Kim, Mourad, Jean-Jacques, Boersma, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418510/
https://www.ncbi.nlm.nih.gov/pubmed/22511654
http://dx.doi.org/10.1093/eurheartj/ehs075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418510/
https://www.ncbi.nlm.nih.gov/pubmed/22511654
http://dx.doi.org/10.1093/eurheartj/ehs075

Ejemplares similares